Premium
Performance evaluation of a line blot assay system for detection of anti‐PM‐Scl antibody in Japanese patients with systemic sclerosis
Author(s) -
Hamaguchi Yasuhito,
Kuwana Masataka,
Takehara Kazuhiko
Publication year - 2019
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.13638
Subject(s) - western blot , antibody , medicine , microbiology and biotechnology , immunoprecipitation , immunology , chemistry , biology , gene , biochemistry
Objective To evaluate the performance of a line blot (LB) assay for identifying anti‐PM‐Scl antibody (Ab). Methods We screened 56 serum samples from systemic sclerosis patients using a protein immunoprecipitation (IP) assay and an LB assay (Systemic Sclerosis Profile Euroline® Blot test kit) to detect anti‐PM‐Scl Ab. We compared the results obtained by the IP and LB assays. Results Among the 56 serum samples of SSc patients, 9 sera were positive for anti‐PM‐Scl75 Ab and 1 for anti‐PM‐Scl100 Ab by the LB assay. The protein IP assay revealed that none of the samples precipitated 75 or 100 kDa proteins identical to the anti‐PM‐Scl Ab reference serum, regardless of the positive or negative results obtained in the LB assay. Therefore, the false‐positive rates for both anti‐PM‐Scl75 Ab and anti‐PM‐Scl100 Ab by the LB assay were 100%. Conclusion Detection of anti‐PM‐Scl Ab assessed with a commercial LB assay requires extreme caution since it may yield false‐positive data.